Abstract:Vaccination of the reservoir species is a key component in the global fight against rabies. For wildlife reservoir species and hard to reach spillover species (e. g. ruminant farm animals), oral vaccination is the only solution. In search for a novel potent and safe oral rabies vaccine, we generated a recombinant vector virus based on lentogenic Newcastle disease virus (NDV) strain Clone 30 that expresses the glycoprotein G of rabies virus (RABV) vaccine strain SAD L16 (rNDV_G RABV ). Transgene expression and virus replication was verified in avian and mammalian cells. To test immunogenicity and viral shedding, in a proof-of-concept study six goats and foxes, representing herbivore and carnivore species susceptible to rabies, each received a single dose of rNDV_G RABV (10 8.5 TCID 50 /animal) by direct oral application. For comparison, three animals received the similar dose of the empty viral vector (rNDV). All animals remained clinically inconspicuous during the trial. Viral RNA could be isolated from oral and nasal swabs until four (goats) or seven days (foxes) post vaccination, while infectious NDV could not be re-isolated. After four weeks, three out of six rNDV_G RABV vaccinated foxes developed RABV binding and virus neutralizing antibodies. Five out of six rNDV_G RABV vaccinated goats displayed RABV G specific antibodies either detected by ELISA or RFFIT. Additionally, NDV and RABV specific T cell activity was demonstrated in some of the vaccinated animals by detecting antigen specific interferon γ secretion in lymphocytes isolated from pharyngeal lymph nodes. In conclusion, the NDV vectored rabies vaccine rNDV_G RABV was safe and immunogenic after a single oral application in goats and foxes, and highlight the potential of NDV as vector for oral vaccines in mammals. Oral vaccination of rabies reservoir and spill-over species is the key to control the disease and prevent human rabies. In the past, baits containing live-attenuated rabies vaccines decreased significantly carnivore-mediated rabies in Central and Western Europe as well as North America. However, certain susceptible species are refractory to the oral immunization using so far licensed vaccines. Our vector vaccine based on avian Newcastle disease virus (NDV) has the potential to contribute to the targeted rabies eradication as it was safe and immunogenic after oral administration in goats and foxes. A single vaccine application elicited a rabies virus (RABV) specific systemic humoral immune response in the majority of the vaccinated animals as well as RABV specific T cells in some of the vaccinated animals. NDV can be manufactured at low-cost using already existing infrastructure of influenza vaccines, opening new possibilities especially for middle- and low-income countries that suffer under the economically burden of rabies.

A Novel Rabies Vaccine Based on a Recombinant Bovine Herpes Virus Type 1 Expressing Rabies Virus Glycoprotein

Cell Surface Display of Rabies Virus Glycoprotein by Using Ice Nucleation Protein

A Novel Rabies Vaccine Based on a Recombinant Parainfluenza Virus 5 Expressing Rabies Virus Glycoprotein.

A novel mRNA rabies vaccine as a promising candidate for rabies post-exposure prophylaxis protects animals from different rabies viruses

Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice

Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells

A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice

An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice

A Novel Rabies Vaccine Based on the Chimpanzee Adenoviral Vector AdC68

Recombinant Rabies Virus with the Glycoprotein Fused with a DC-binding Peptide is an Efficacious Rabies Vaccine.

Recombinant Adeno-Associated Virus Serotype 9 AAV-RABVG Expressing a Rabies Virus G Protein Confers Long-Lasting Immune Responses in Mice and Non-Human Primates

Construction and Evaluation of Recombinant Lactobacillus Plantarum NC8 Delivering One Single or Two Copies of G Protein Fused with a DC-targeting Peptide (dcpep) As Novel Oral Rabies Vaccine.

A single dose of an ALVAC vector-based RABV virus-like particle candidate vaccine induces a potent immune response in mice, cats and dogs

A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge.

Codon Optimization of G Protein Enhances Rabies Virus-Induced Humoral Immunity

Immune response after oral immunization of goats and foxes with an NDV vectored rabies vaccine candidate

AAV-expressed G protein induces robust humoral and cellular immune response and provides durable protection from rabies virus challenges in mice

An mRNA vaccine against rabies provides strong and durable protection in mice

A rabies mRNA vaccine provides a rapid and long-term immune response in mice

Preparation and diagnostic use of a novel recombinant single-chain antibody against rabies virus glycoprotein

A Recombinant Canine Distemper Virus Expressing a Modified Rabies Virus Glycoprotein Induces Immune Responses in Mice